Polyphor’s Balixafortide Demonstrates Consistent Dual Action Anti-Viral and Anti-Inflammatory Activity in COVID-19 Preclinical Trials

NEXT STORY
Healthcare PPE Market to Reach USD 27,264.4 Million by 2028; Rising COVID-19 Cases Worldwide to Augment Growth, States Fortune Business Insights™
PREV STORY
Santhera and ReveraGen Announce Positive and Statistically Highly Significant Topline Results with Vamorolone in Pivotal VISION-DMD Study
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Kamada Announces Top-line Results from its Phase 1/2 Clinical Trial of its Plasma-Derived Hyperimmune Globulin (IgG) Treatment for Coronavirus Disease (COVID-19)

author_avatar
NASDAQ Market News

Galena Biopharma to Report Third Quarter 2016 Financial Results and Provide a Corporate Update on Wednesday, November 9, 2016

SAN RAMON, Calif., Oct. 26, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma (NASDAQ:GALE), a biopharmaceutical ...

author_avatar
NASDAQ Market News

The Worldwide Immunoassay Industry is Expected to Reach $39 Billion by 2026 at a CAGR of 6.6% from 2021

author_avatar
NASDAQ Market News